Ascendis Pharma reveals positive trial data for achondroplasia treatments at ICCBH 2026.

Ascendis Pharma announced new clinical data on its treatments for children with achondroplasia, presented at ICCBH 2026. The data show improvements in lower-extremity alignment and skeletal dysplasia symptoms from their TransCon CNP and combination therapy with TransCon hGH. TransCon CNP was FDA-approved in early 2026 and is under review in Europe. These findings highlight potential benefits for managing achondroplasia complications and support ongoing development of these therapies.